Comparative Effects of Weight Loss and Incretin-Based Therapies on Endothelial Vasodilatory and Fibrinolytic Function - Mashayekhi, Mona; Beckman, Joshua A.; Nian, Hui; Garner, Erica M.; Mayfield, Dustin; Wright, Patricia; Howard, Sara E.; Perkins, Bradley; Olson, Dianna; Snyder, William E.; Devin, Jessica K.; Koethe, John R.; et al. (medRxiv, 2022)
Background Glucagon-like peptide-1 receptor (GLP1R) agonists decrease cardiovascular events in patients with type 2 diabetes, and cause weight loss regardless of diabetes status. The contribution of weight loss to the cardiovascular benefits of GLP1R agonists is unknown.Methods Obese pre-diabetic individuals were randomized to 14 weeks of the GLP1R agonist liraglutide, hypocaloric diet-mediated weight loss, or the dipeptidyl peptidase 4 inhibitor sitagliptin as an incretin-based drug comparator. Treatment with drug was double blind and placebo-controlled. Weight, metabolic and hemodynamic measures, endothelium-dependent vasodilation and fibrinolytic function were measured at baseline and after 2 and 14 weeks of treatment.Results Liraglutide and diet reduced weight, fasting blood glucose, and insulin resistance at 14 weeks, while sitagliptin did not. There was no significant effect of any treatment on endothelial vasodilatory function as measured by flow-mediated dilation (FMD). Because baseline endothelial function was normal in the overall cohort, post-hoc subgroup analyses were conducted in participants stratified by FMD below or above the median for gender. All three treatments improved FMD at 2 weeks in individuals with baseline endothelial dysfunction and sitagliptin and diet also improved endothelium-dependent vasodilation at 14 weeks. Liraglutide and diet reduced plasminogen activator inhibitor-1 (PAI-1) at 14 weeks. GLP1R antagonism with exendin (9-39) increased fasting blood glucose but did not change FMD or PAI-1 in the overall group. Exendin (9-39) attenuated the increase in FMD in the sitagliptin-treated group at two weeks.Conclusions Liraglutide and diet cause weight loss, improve insulin resistance and reduce PAI-1 at 14 weeks. The effect on PAI-1 is GLP1R-independent. In individuals with low baseline FMD, sitagliptin and diet improve FMD at two and 14 weeks, while liraglutide improves FMD at two weeks.Clinical Trial Registration NCT03101930 https://clinicaltrials.gov/ct2/show/NCT03101930Competing Interest StatementJ.A.B.: Dr. Beckman is a consultant for JanOne, serves on a DSMB for Janssen and Novartis, and has ownership in EMX and Janacare. J.R.K: Dr. Koethe has served as a consultant to Gilead Sciences, Merck, ViiV Healthcare, Theratechnologies and Janssen. He has also received research support from Gilead Sciences and Merck. N.J.B.: Dr. Brown serves on the scientific advisory board for Alnylam Pharmaceuticals. She serves as a consultant for Pharvaris Gmbh. Clinical TrialNCT03101930Funding StatementResearch reported in this publication was supported by the American Heart Association 17SFRN33520017 (M.M., J.A.B., H.N., D.M., P.W., S.E.H., B.P., D.O., J.R.K., C.Y., H.S., J.M.L, N.J.B), National Center for Advancing Translational Sciences 5UL1TR002243, National Institute of Diabetes and Digestive and Kidney Diseases T32DK007061 (M.M), National Institute of Allergy and Infectious Diseases U19AI095227 (K.N.C), National Heart, Lung and Blood Instituted R01HL146654 (J.D.B). This work utilized the core(s) of the Vanderbilt Diabetes Research and Training Center funded by grant DK020593 from the National Institute of Diabetes and Digestive and Kidney Disease. Novo Nordisk provided liraglutide and matching placebo.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Vanderbilt Institutional Review Board, registered at clinicaltrials.gov NCT03101930, and conducted according to the Declaration of Helsinki. All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.DPP4Dipeptidyl peptidase 4FMDFlow-mediated dilationGLP-1Glucagon-like peptide-1GLP1RGlucagon-like peptide-1 receptorGLSGeneralized least squaresHbA1cHemoglobin A1cHOMA-IRHomeostatic Model Assessment for Insulin ResistanceHOMA2Homeostatic Model Assessment 2NMDNitroglycerin-mediated dilationOGTTOral glucose tolerance testPAI-1Plasminogen activator inhibitor-1T2DMType 2 diabetes mellitusUACRUrine albumin-to-creatinine ratio